246 related articles for article (PubMed ID: 15585981)
1. The innate immune response in the central nervous system and its role in glioma immune surveillance.
Friese MA; Steinle A; Weller M
Onkologie; 2004 Oct; 27(5):487-91. PubMed ID: 15585981
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of local immunoresistance in glioma.
Albesiano E; Han JE; Lim M
Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
[TBL] [Abstract][Full Text] [Related]
3. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-based immunotherapy for malignant gliomas.
Akasaki Y; Black KL; Yu JS
Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
[TBL] [Abstract][Full Text] [Related]
5. Innate immune recognition and suppression of tumors.
Hayakawa Y; Smyth MJ
Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
[TBL] [Abstract][Full Text] [Related]
6. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
7. Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the immune system against human glioma.
Dhodapkar KM; Banerjee D; Steinman RM
Ann N Y Acad Sci; 2005 Dec; 1062():13-21. PubMed ID: 16461784
[TBL] [Abstract][Full Text] [Related]
9. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
Pollack IF; Okada H; Chambers WH
Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
[TBL] [Abstract][Full Text] [Related]
11. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials in cellular immunotherapy for brain/CNS tumors.
Badhiwala J; Decker WK; Berens ME; Bhardwaj RD
Expert Rev Neurother; 2013 Apr; 13(4):405-24. PubMed ID: 23545055
[TBL] [Abstract][Full Text] [Related]
13. Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas.
Janelidze S; Bexell D; Badn W; Darabi A; Smith KE; Fritzell S; Gunnarsson S; Milos P; Bengzon J; Salford LG; Siesjö P; Visse E
J Immunother; 2009; 32(6):593-601. PubMed ID: 19483650
[TBL] [Abstract][Full Text] [Related]
14. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg.
Biollaz G; Bernasconi L; Cretton C; Püntener U; Frei K; Fontana A; Suter T
Eur J Immunol; 2009 May; 39(5):1323-33. PubMed ID: 19337997
[TBL] [Abstract][Full Text] [Related]
15. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
16. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
Lee Y; Bigner DD
Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
[TBL] [Abstract][Full Text] [Related]
17. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
18. [Immunology of the central nervous system and brain tumors].
Tybor K
Neurol Neurochir Pol; 1992; 26(6):853-9. PubMed ID: 1301513
[TBL] [Abstract][Full Text] [Related]
19. Microglia and central nervous system immunity.
Kaur G; Han SJ; Yang I; Crane C
Neurosurg Clin N Am; 2010 Jan; 21(1):43-51. PubMed ID: 19944965
[TBL] [Abstract][Full Text] [Related]
20. [A new experimental approach to the specific adoptive immunotherapy for malignant gliomas].
Yamasaki T
Nihon Geka Hokan; 1983 Nov; 52(6):783-801. PubMed ID: 6331809
[No Abstract] [Full Text] [Related]
[Next] [New Search]